SABCS 2021

Genomic signatures of DCIS

Leading the way for other ct-DNA trials

Hypothesis-generating study in the HER2-enriched…

Re-evaluation confirms old data

The risk-adapted decision for or against AI has to be…

Metformin is not an anti-cancer drug

Critical consideration of the study data is necessary

The next standard for TNBC?!

Solved and unsolved controversies of early breast…

Benefit only related to chemotherapy?!

Metformin shows no efficacy for most cancer patients

Molecular-guided treatment is of value in combination…

Negative results with hope for translational projects

"Signatures Genomiche " nel carcinoma duttale in situ

La metformina non può essere considerata un farmaco…

Negative Ergebnisse, aber Hoffnung für translationale…

Erneute Auswertung bestätigt alte Daten

Hypothesen-generierende Studie beim HER2-enriched…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Kritische Betrachtung der Studiendaten notwendig

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

TNBC EBC: What is the new neoadjuvant standard…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

Exciting novel therapies for metastatic TNBC

TROP2 - new target for improved chemotherapy

Samuraciclib - new targeted therapy for luminal breast…

Oral SERDs for early setting and adjuvant therapy

Switching with molecular progress improves PFS

Dato-DXd new promising ADC

Elacestrant - less than we expected

Best of the year: systemic therapy

TDXd is very efficient in patients with brain…

Very good news for endocrine resistant metastatic…

Robust benefit of pembroluzimab in addition to…

My highlights of 2021 in metastatic breast cancer

T-Dxd is also active in patients with brain metastasis

Chekpoint inhibition in breast cancer

Pooled analyses shows OS benefit for most subgroups

Dato-Dxd for metastatic TNBC

Oral SERDs are efficient, but show high progression…

Imaging with mass cytometry can provide predictive…

Final results of the CPS score subgroup analyses show…

Pioneering study of personalized medicine in advanced…

PFS improvement with fulvestrant in patients with…

Reconfirming effect of T-DXd in patients with brain…

Activity of T-Dxd across all Her2-expressing breast…

Precision oncology is beneficial in certain mBC…

Effectiveness depending on PDL1 status

3 updates - 3 new standards of care

Promising results for TNBC patients

Patients with BRCA2 don't show PFS benefit with CDK4/6i

IO + IO without resounding success in the mBC setting

Immuntherapy for high tumor mutation burden in…

Amazing period for patients with refractory metastatic…

Which patients will benefit from Pembro in metastatic…

Activité du T-DXd dans les metastases cérébrales

Buone notizie per i tumori mammari endocrino resistenti

Präzisionsonkologie funktioniert beim mBC

Elacestrant – poniżej oczekiwań

È un grande momento per i pazienti con tumore mammario…

Amélioration de la survie sans progression par le…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

IO + IO ohne durchschlagenden Erfolg beim mBC

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Umstellung bei molekularem Progress verlängert PFS

Best of the Year: Systemtherapie

Resultados finales de los análisis de los subgrupos de…

Samuracyklib – nowe leczenie celowane w rakach…

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Résultats prometteurs dans le cancer du sein triple…

Mi retrospectiva del cáncer de mama metastático en 2021

L’imaging mass cytometry può aiutare a predire…

Wegweisende Daten für die personalisierte Medizin beim…

Neues Target für optimierte Chemotherapie

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Risultati promettenti nel tumore al seno triplo…

Werden orale SERDs die Therapie mit Fulvestrant in…

Checkpoint-Inhibition beim Mammakarzinom

T-Dxd aktywny również w przerzutach do mózgu

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Integrating patients perspectives in metastatic breast…

MBC HR+: What is the best option after a CDK4/6i…

MBC TNBC: Molecular tumor characteristics define the…

Targeting rare mutations in breast cancer - is this the…

Therapy of brain metastasis – can T-DXd be the new SoC?

Are SERDs a future therapy for endocrine resistant…

New ADCs on the horizon for TNBC patients